Scienture Holdings Inc (SCNX)

$0.64 -0.03 (-4.28%)
Market Cap 26.14M
Revenue (ttm) 140,000.00
Net Income (ttm) 9.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 6,478.57%
Debt to Equity Ratio 0.01
Volume 2,141,800
Avg Vol 27,113,736
Day's Range N/A - N/A
Shares Out 40.63M
Stochastic %K 4%
Beta 3.04
Analysts Strong Buy
Price Target N/A

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 800 261 0281
Address:
6308 Benjamin Rd, Suite 708, Tampa, United States
Krr511970
Krr511970 Nov. 17 at 2:00 AM
$SCNX need a short killer, who can help? With new revenue and highly capitalized and two approved drugs, shorts should be a catalyst for a 20x rise. This should be easy shorts cannot continue
1 · Reply
Krr511970
Krr511970 Nov. 16 at 11:10 PM
$SCNX Need Eric Jackson or some anti short activist. Reddit meme this.
0 · Reply
Note7Creole
Note7Creole Nov. 16 at 4:47 PM
$SCNX remember this!?🤔
0 · Reply
BinaryLogic
BinaryLogic Nov. 16 at 1:56 PM
$SCNX [Opportunity] Read the latest ER and Corporate SH meeting. The Company launched Arbli on 8/15, and in 1.5mos generated nearly $600K revenue, which equates to nearly $5M annualized run rate. This is before scaling/expanding. Again-15% market penetration anticipated to appx $40M annualized revenue, strong margins (97% GM in Q3) and valuation 2-4x P/S, $80-160M valuation on Arbli alone against $20M market cap. Rezenopy to launch in Q1-2026, which will be accretive to that valuation and I have already shown DCF to the board on BOTH multiple times in the past, including all assumptions, calculations. The vote to increase OS to 8B was rejected, RSS approved. Watch for possible fallout on RSS announcement which is mis-guided (IMO), double bottom to $0.4-0.5. 10-15:1 RSS will create (IMO) undervalued microfloat with strong upside on scaling both leading FDA approved drugs on strong margins, low Overhead while progressing on balance of product pipeline. https://www.stocktitan.net/news/SCNX/scienture-reports-q3-2025-financial-results-and-provides-business-ca37jxownwky.html
3 · Reply
Ecki98
Ecki98 Nov. 15 at 9:33 AM
$SCNX hier stimmt was nicht …. Das Wirt bald was passieren Welche Richtung ist noch fragwürdig …
1 · Reply
Krr511970
Krr511970 Nov. 15 at 5:22 AM
$SCNX Nov 14 "The stockholders of the Company rejected the amendment to the Charter to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares" 8k report
0 · Reply
Rohtan
Rohtan Nov. 14 at 9:33 PM
$SCNX it’s coming back to my original average.57. I think we will see a RS the way it is going
1 · Reply
Diverstj981
Diverstj981 Nov. 14 at 7:45 PM
$SCNX Down 17% from today's high. C'mon already.
0 · Reply
MarketWarfare
MarketWarfare Nov. 14 at 7:02 PM
$SCNX SCNX CEO watching the ever dropping share price.
2 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 14 at 6:20 PM
$SCNX another bio small name that reported great news yesterday..... im accumulating. Could pop at anytime... I can wait...
1 · Reply
Latest News on SCNX
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Nov 13, 2025, 8:05 AM EST - 3 days ago

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Nov 4, 2025, 8:05 AM EST - 12 days ago

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Oct 23, 2025, 8:05 AM EDT - 24 days ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Oct 16, 2025, 9:00 AM EDT - 4 weeks ago

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Wellgistics Health Announces Executive Management and Board Changes

Oct 13, 2025, 8:00 AM EDT - 4 weeks ago

Wellgistics Health Announces Executive Management and Board Changes

WGRX

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Sep 16, 2025, 8:05 AM EDT - 2 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 14, 2025, 9:00 AM EDT - 3 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Aug 13, 2025, 8:05 AM EDT - 3 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 4 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 4 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 5 months ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 6 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 6 months ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 6 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 8 months ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 8 months ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 8 months ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 8 months ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 9 months ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 10 months ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 11 months ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 1 year ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 1 year ago

Trxade health, Inc files its 3Q 10Q

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Aug 3, 2023, 9:05 AM EDT - 2 years ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

Jul 31, 2023, 8:35 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Jul 14, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

Jun 30, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

Jun 23, 2023, 4:40 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Jun 23, 2023, 3:00 PM EDT - 2 years ago

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

Jun 23, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

Jun 21, 2023, 12:36 PM EDT - 2 years ago

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

Krr511970
Krr511970 Nov. 17 at 2:00 AM
$SCNX need a short killer, who can help? With new revenue and highly capitalized and two approved drugs, shorts should be a catalyst for a 20x rise. This should be easy shorts cannot continue
1 · Reply
Krr511970
Krr511970 Nov. 16 at 11:10 PM
$SCNX Need Eric Jackson or some anti short activist. Reddit meme this.
0 · Reply
Note7Creole
Note7Creole Nov. 16 at 4:47 PM
$SCNX remember this!?🤔
0 · Reply
BinaryLogic
BinaryLogic Nov. 16 at 1:56 PM
$SCNX [Opportunity] Read the latest ER and Corporate SH meeting. The Company launched Arbli on 8/15, and in 1.5mos generated nearly $600K revenue, which equates to nearly $5M annualized run rate. This is before scaling/expanding. Again-15% market penetration anticipated to appx $40M annualized revenue, strong margins (97% GM in Q3) and valuation 2-4x P/S, $80-160M valuation on Arbli alone against $20M market cap. Rezenopy to launch in Q1-2026, which will be accretive to that valuation and I have already shown DCF to the board on BOTH multiple times in the past, including all assumptions, calculations. The vote to increase OS to 8B was rejected, RSS approved. Watch for possible fallout on RSS announcement which is mis-guided (IMO), double bottom to $0.4-0.5. 10-15:1 RSS will create (IMO) undervalued microfloat with strong upside on scaling both leading FDA approved drugs on strong margins, low Overhead while progressing on balance of product pipeline. https://www.stocktitan.net/news/SCNX/scienture-reports-q3-2025-financial-results-and-provides-business-ca37jxownwky.html
3 · Reply
Ecki98
Ecki98 Nov. 15 at 9:33 AM
$SCNX hier stimmt was nicht …. Das Wirt bald was passieren Welche Richtung ist noch fragwürdig …
1 · Reply
Krr511970
Krr511970 Nov. 15 at 5:22 AM
$SCNX Nov 14 "The stockholders of the Company rejected the amendment to the Charter to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares" 8k report
0 · Reply
Rohtan
Rohtan Nov. 14 at 9:33 PM
$SCNX it’s coming back to my original average.57. I think we will see a RS the way it is going
1 · Reply
Diverstj981
Diverstj981 Nov. 14 at 7:45 PM
$SCNX Down 17% from today's high. C'mon already.
0 · Reply
MarketWarfare
MarketWarfare Nov. 14 at 7:02 PM
$SCNX SCNX CEO watching the ever dropping share price.
2 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 14 at 6:20 PM
$SCNX another bio small name that reported great news yesterday..... im accumulating. Could pop at anytime... I can wait...
1 · Reply
FishFace09
FishFace09 Nov. 14 at 6:13 PM
$SCNX hate to say it but this gonna be a longer hold than expected, by next earning we will be golden tho
0 · Reply
Jones79
Jones79 Nov. 14 at 5:48 PM
$SCNX Dirty Bastard!!
0 · Reply
pAmdd
pAmdd Nov. 14 at 4:57 PM
$SCNX now outstanding is 40 million ? How come
0 · Reply
JackCampbell
JackCampbell Nov. 14 at 4:21 PM
$SCNX Institutional investors are loading! https://fintel.io/so/us/scnx
1 · Reply
pAmdd
pAmdd Nov. 14 at 3:40 PM
$SCNX I sold can’t hold this any longer something is wrong here we was good
0 · Reply
pAmdd
pAmdd Nov. 14 at 2:34 PM
$SCNX unbelievable
1 · Reply
DirkaDirkaaaaaa
DirkaDirkaaaaaa Nov. 14 at 1:35 PM
I've got over 50+ stocks on Robinhood watchlists and so far today the only thing green is $SCNX. Little by little 😂
1 · Reply
Blnun
Blnun Nov. 14 at 1:30 PM
$SCNX Not sure what s moven here but I am watching to learn. We will learn the agenda soon. Everything for a reason right. ???😏
0 · Reply
DW65
DW65 Nov. 14 at 11:53 AM
$SCNX this may help you out
0 · Reply
brat1985
brat1985 Nov. 14 at 11:50 AM
$SCNX when is earnings date?
0 · Reply
Mula_Win
Mula_Win Nov. 14 at 10:42 AM
$BTC.X Bits Melting Down now 96K 1 Bit Can Buy 135K Shares of $SCNX with 2FDA approved Drugs in Commercial Sales/Distribution and Prescription ✅BTC No 100% Potential Gain from Current Price LongTerm ✅$SCNX 500% Gain Minimum MidTerm
0 · Reply
TopRunners
TopRunners Nov. 14 at 9:32 AM
Ticker ARBB is making a move.. Could ARBB be todays big squeeze?! 700k shares float.. watchers on ARBB are growing very fast. Would not be surprised if ARBB is todays big runner. 8$+ break could send her parabolic! $YDKG $BFLY $CTM $SCNX ARBB on the move
0 · Reply